Navigation Links
Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
Date:12/10/2008

TUSTIN, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has entered into a loan agreement for up to $10 million in proceeds. The initial funding of $5 million is expected to close within the next 10 days. The loan agreement includes an option to acquire a second $5 million tranche in the future, upon Peregrine's satisfaction of certain conditions. MidCap Financial LLC and BlueCrest Capital Finance, L.P. are providing the debt financing. Proceeds will be used to help fund the company's seven ongoing clinical trials in cancer and serious viral diseases and for general corporate purposes.

"In this extraordinarily difficult financing environment, we are pleased to have entered into this loan agreement with two organizations with extensive experience in the healthcare field," said Paul J. Lytle, CFO of Peregrine. "This capital infusion will enable us to continue advancing our clinical programs without tapping into the equity markets during these challenging market conditions. We are optimistic that this loan will enable us to achieve a number of value-driving clinical milestones over the coming months, enabling us to progress these programs while waiting for the current financial turbulence to subside."

Under the terms of the 36-month loan agreement, upon closing Peregrine will receive a first tranche of $5 million. For the first six months, the payments are interest-only, followed by principal and interest payments amortized over the next 30 months. Peregrine has the option to acquire the second $5 million tranche if a number of conditions are met, including generating cash from other sources and also achieving certain pre-determined clinical trial end-points. The terms of the agreement also include a provision for warrant coverage equal to 10%
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... St. Francis, WI (PRWEB) November 23, 2014 ... based manufacturer and supplier of fine chemical ingredients ... industries announced the launch of its new website, ... a description of Apiscent Labs, clean design, easy ... qualities that make Apiscent Labs stand out. ...
(Date:11/22/2014)... Two new educational webinars hosted by ... ALS research and how the pharmaceutical industry can make life ... Challenge: Where Does the ALS Money Go? , Featuring guest ... Time: 1:30pm ET, Register to attend , This ... Cudkowicz, Julianne Dorn Professor of Neurology at Massachusetts General Hospital ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp ... surround himself with great people and take risks to ... often marveled at his extraordinarily courageous attitude when taking ... -- even with his death impending—that’s how he continued ... would ultimately take his life. , Carrying on Sharp’s ...
(Date:11/22/2014)... Boston, MA (PRWEB) November 21, 2014 ... and key investors will gather on December 3rd ... Boston Biotech Conferences series. GeneticRx will take place ... Harvard Medical School and will discuss the present ... gene therapy, exon skipping, and gene editing—as well ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2
... ... an extension of a company,s clinical team to deliver greater visibility and control over ... ... ), the leading provider of Clinical Trial Operations (CTO) software, today unveiled the ClearTrial ...
... ... ... ... ...
... NY Scientists at the U.S. Department of Energy,s Brookhaven ... bubbles that keep water from wetting a super non-stick surface. ... and the non-stick material the scientists created by "pock-marking" ... meter is being published online today in the journal ...
Cached Biology Technology:ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies 2ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies 3Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 2Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 3Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 4Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 5Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 6Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 7Scientists glimpse nanobubbles on super nonstick surfaces 2Scientists glimpse nanobubbles on super nonstick surfaces 3
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... in Texas has been identified as a new genus and ... Aetodactylus halli is a pterosaur, a group of flying ... pterosaur literally a winged lizard is also one ... family Ornithocheiridae , according to paleontologist Timothy S. Myers, ...
... April 27 /PRNewswire-Asia-FirstCall/ -- Telestone Technologies,Corporation ("Telestone" ... developer,of local access networks, products, and provider of engineering ... it recently opened four,new branch offices in Zhejiang ... provinces. As a,result of forecasted sales of $10.0 ...
... ,, SAN FRANCISCO , April 27, ... announced that several of its,most popular games will be playable on Kongregate, ... through the,Kongregate platform, expanding its consumer audience, and share in revenue,generated from ... , , ...
Cached Biology News:Rare 95 million-year-old flying reptile Aetodactylus halli is new pterosaur genus, species 2Rare 95 million-year-old flying reptile Aetodactylus halli is new pterosaur genus, species 3Rare 95 million-year-old flying reptile Aetodactylus halli is new pterosaur genus, species 4Telestone Technologies Corporation Opens Four New Branch Offices 2Telestone Technologies Corporation Opens Four New Branch Offices 3Telestone Technologies Corporation Opens Four New Branch Offices 4Bigpoint Adds Kongregate to Growing List of Content Distribution Partners 2
... polyclonal antibody to human XAB2 (amino terminus) ... identified through its interaction with XPA. Immunoprecipitation ... of XAB2 interacts with the transcription-coupled repair-specific ... with RNA polymerase II. Microinjection experiments with ...
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: